Cancer-Related Symptom Assessment in Russia: Validation and Utility of the Russian M. D. Anderson Symptom Inventory

Ivanova, Maria; Ionova, Tatyana I.; Kalyadina, S.; Uspenskaya, Olga S.; Kishtovich, Anton V.; Guo, Hong; Mendoza, Tito R.; Novik, Andrei A.; Cleeland, Charles S.; Wang, Xin Shelley

doi:10.1016/j.jpainsymman.2005.04.015

Cited by 52 publications

(67 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,17 The addition of anorexia to this cluster has also been reported, as has the addition of dyspnea. 18,29 The association between fatigue/malaise/lethargy and dehydration has also been reported previously. 28 These findings are reassuring and confirm the clinical relevance of these severe adverse event clusters in the management of symptoms.…”

Section: Discussionsupporting

confidence: 66%

“…[9][10][11] In recent years, symptom clusters have been evaluated across a variety of cancers, [12][13][14] with several studies in breast cancer, [15][16][17] lung cancer, [18][19][20] and non-Hodgkin lymphoma 21 and across multiple cancer sites. [22][23][24][25][26][27][28][29][30][31][32] Each of these studies prospectively collected patient-reported symptoms. Although having patient-reported outcomes is important for the understanding of symptom clusters, they are not always collected in clinical trials.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, the instruments used to measure patient-reported symptoms varied across the studies. Several studies used the MD Anderson symptom inventory, 11,29 whereas others used self-developed symptom checklists. [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]28 The level of detail with which symptoms are collected and the symptoms that are included vary across these instruments.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

ReCAP: Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events

Zhong

Lim

Hershman

et al. 2016

JOP

View full text Add to dashboard Cite

CONTEXT & QUESTION ASKED: Exploring the relationship among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence. To date, symptom cluster studies have used patient-reported data, which are not always available in clinical trials. In this study, we proposed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) to identify adverse event clusters because the CTCAE are collected as standard practice and can therefore be used when patient-reported outcomes are unavailable. Hence, is it feasible to identify severe adverse events clusters from data captured using the CTCAE in clinical trials? SUMMARY ANSWER: Six severe adverse events clusters were identified in patients with advanced prostate cancer. Identifying adverse events clusters using CTCAE data from clinical trials is feasible. METHODS: A variable-based hierarchical cluster analysis was conducted using the CTCAE data captured from 323 patients who experienced at least one grade 3 or higher adverse event in an advanced prostate cancer randomized clinical trial conducted by SWOG (S9916). BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: The difficulty of using adverse event data from clinical trials is that often not all adverse events are recorded. In our study, only the highest severity grade for each adverse event type was recorded, and only grade 3 or higher adverse events were captured reliably. Moreover, in contrast to previous publications on symptom cluster that used patient-reported outcomes, the CTCAE is clinician reported and may not accurately reflect the presence of patient symptoms and the severity of these symptoms. REAL-LIFE IMPLICATIONS: Capturing adverse events using the CTCAE, which is standard practice in all clinical trials, can be used to understand the relationships among adverse events and to identify adverse events clusters when patient-reported outcomes are unavailable. [Figure: see text]

show abstract

Section: Discussionsupporting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ReCAP: Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events

Zhong

Lim

Hershman

et al. 2016

JOP

View full text Add to dashboard Cite

show abstract

“…The development and validation process for the MDASI have been reported elsewhere. 8,11 Patients were asked to complete the MDASI at baseline before starting chemoradiation, weekly during chemoradiation, and monthly after the completion of chemoradiation. The first followup after treatment was coincident with the restaging CT scan (around day 94 from initiation of therapy).…”

Section: Assessment Of Symptoms and Functional Impairmentmentioning

confidence: 99%

Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation

Reyes‐Gibby

Chan

Abbruzzese

et al. 2007

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Pancreatic cancer is a lethal disease characterized by multiple disease-related symptoms. Chemoradiation therapy is a standard of treatment for locally advanced pancreatic cancer. Although shown to prolong survival, there is little information about treatment-related symptoms or the palliative benefits of chemoradiation. We assessed symptoms of patients with locally advanced pancreatic cancer receiving chemoradiation to determine the prevalence, and co-occurrence, of symptoms and to identify the extent to which symptoms interfered with function. Forty-eight patients were treated with chemoradiation on a Phase I protocol. Patients received radiotherapy (50.4 Gy in 28 fractions), capecitabine (median dose 825 mg/m 2 twice daily), and bevacizumab (2.5-10 mg/kg). Symptom severity and its interference with function were prospectively assessed (at presentation, NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript during, and after chemoradiation) in 43 consenting patients using the M.D. Anderson Symptom Inventory. Results showed that 95% of patients reported at least one of the 13 symptoms assessed at presentation. The most commonly reported symptoms of moderate to severe (≥5 on a 0-10 scale) intensity at presentation were lack of appetite (24%), pain (19%), fatigue (19%), and sleep disturbance (10%). We observed an increase in patients reporting moderate to severe fatigue, nausea, and sleep disturbance during chemoradiation. McNemar tests for paired binary observations showed the proportion of patients reporting moderate to severe symptoms significantly (P < 0.001) decreased after chemoradiation at 94 days follow-up (lack of appetite = 7%, pain = 7%, fatigue = 13%, sleep disturbance = 7%). This study demonstrates the feasibility and usefulness of symptom assessment in chemoradiation protocols. Future studies with larger cohorts are needed to further characterize multiple symptoms associated with chemoradiation.

show abstract

“…The MDASI was linguistically and psychometrically validated in Japanese (8) , Greek (9) , Chinese (10) , Russian (11) , Korean (12) , Thai (13) , Filipino (14) , Arabic (15) and French (16) . However, in Brazil this instrument had only linguistic validation (5) , which demonstrated the need for its psychometric validation.…”

Section: Introductionmentioning

confidence: 99%

Portuguese validation of the Symptom Inventory of the M.D. Anderson Cancer Center

Kolankiewicz

Domenico

Lopes

et al. 2014

Rev. esc. enferm. USP

View full text Add to dashboard Cite

Portuguese validation of the symptom inventory of the m.D. Anderson cancer center * RESUMEN Objetivo: Analizar la confiabilidad y la validad de las propiedades psicométricas de la versión brasileña del instrumento de evaluación de síntomas, titulado Inventario de Síntomas del M.D. Anderson -core. Método: Estudio transversal del que participaron 268 pacientes con cáncer en tratamiento ambulatorio, del Municipio de Ijuí, Rio Grande do Sul, Brasil. Resultados: El Alfa de Cronbach MDASI general, los síntomas y las interferencias fueron respectivamente (0,857), (0,784) y (0,794). El análisis factorial demostró la adecuación de los datos (0,792). Se identificaron cuatro factores de los principales componentes relacionados con los síntomas. Factor I: problemas de sueño, preocupaciones, dificultades de recordar las cosas y tristeza. Factor II: mareo, náuseas, falta de apetito y vómito. Factor III: somnolencia, boca seca, adormecimiento y hormigueo. Factor IV: dolor, fatiga y falta de aliento. Se evidenció un solo factor en el componente interferencias en la vida (0,780), prevaleciendo para la actividad en general (59,7%), trabajo (54,9%) y para caminar (49,3%). Conclusión: La versión brasileña del Inventario de M.D. Anderson-core mostró propiedades psicométricas adecuadas en la población evaluada. DESCRIPTORES ABSTRACTObjective: To analyze the reliability and validity of the psychometric properties of the Brazilian version of the instrument for symptom assessment, titled MD Anderson Symptom Inventory -core. Method: A cross-sectional study with 268 cancer patients in outpatient treatment, in the municipality of Ijuí, state of Rio Grande do Sul, Brazil. Results: The Cronbach's alpha for the MDASI general, symptoms and interferences was respectively (0.857), (0.784) and (0.794). The factor analysis showed adequacy of the data (0.792). In total, were identified four factors of the principal components related to the symptoms. Factor I: sleep problems, distress (upset), difficulties in remembering things and sadness. Factor II: dizziness, nausea, lack of appetite and vomiting. Factor III: drowsiness, dry mouth, numbness and tingling. Factor IV: pain, fatigue and shortness of breath. A single factor was revealed in the component of interferences with life (0.780), with prevalence of activity in general (59.7%), work (54.9%) and walking (49.3%). Conclusion:The Brazilian version of the MD Anderson Symptom Inventory -core showed adequate psychometric properties in the studied population.

show abstract

Cancer-Related Symptom Assessment in Russia: Validation and Utility of the Russian M. D. Anderson Symptom Inventory

Cited by 52 publications

References 21 publications

ReCAP: Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events

ReCAP: Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events

Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation

Portuguese validation of the Symptom Inventory of the M.D. Anderson Cancer Center

Contact Info

Product

Resources

About